Columbia University researchers have created engineered probiotic bacteria that train the immune system to destroy cancer cells, paving the way for a new class of cancer vaccines that take advantage of the bacteria’s natural properties to target the tumor.

Bacteria have been used in the treatment of cancer as early as the late 19th century, and are still used today as a therapeutic agent in patients with early-stage bladder cancer.

In this study, scientists made multiple genetic modifications to a probiotic strain of E.coli bacteria to precisely control how the bacteria interact with and train the immune system to cause tumor eradication.

Modified bacterial cells (purple) activate various parts of the immune system to attack cancer cells (grey). Credit: Columbia University

The new study

The research, published in the journal Nature, used mouse models with advanced colon cancer and melanoma.

The vaccine developed boosted the immune system to suppress the growth or in many cases eradicate primary and metastatic cancer while leaving healthy parts of the body unaffected.

As the researchers point out, these vaccines can be personalized to attack the primary tumor and metastases in each individual, but also to prevent future recurrences.